Contribute Try STAT+ Today

As the Trump administration seeks ways to pressure other countries over drug pricing, the U.S. Trade Representative is reportedly being encouraged to revamp a trade agreement with Colombia, in part to force the South American nation to alter policies that have upset the pharmaceutical industry.

The move comes in response to ongoing concerns by the pharmaceutical industry that the Colombian government continues to consider the use of compulsory licensing to create lower-cost alternatives to expensive medicines, according to World Trade Online. U.S. Trade Rep Robert Lighthizer is also reportedly being urged to examine government policies in Chile and Peru over the same issue. A U.S. Trade Rep spokeswoman wrote us that the agency did not confirm the report; she also did not deny it.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.